When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Gestational diabetes mellitus

Last reviewed: 22 Nov 2024
Last updated: 06 Dec 2024

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors (usually asymptomatic)
Full details

Other diagnostic factors

  • polyuria
  • polydipsia
  • fetal macrosomia in a previous pregnancy
Full details

Risk factors

  • elevated BMI
  • previous gestational diabetes
  • previous macrosomic baby
  • family history of diabetes mellitus
  • non-white ancestry
  • advanced maternal age (>40 years)
  • polycystic ovarian syndrome (PCOS)
Full details

Diagnostic investigations

1st investigations to order

  • oral glucose tolerance test
Full details

Investigations to consider

  • random blood (plasma) glucose
  • HbA1c
  • fasting plasma glucose
Full details

Treatment algorithm

ACUTE

fasting plasma glucose ≥7 mmol/L (≥126 mg/dL), or 6 to 6.9 mmol/L (108-124 mg/dL) if large fetus/polyhydramnios

fasting plasma glucose <7 mmol/L (<126 mg/dL) without large fetus/polyhydramnios

labour

Contributors

Authors

Eleanor Scott, BM, BS, MD, FRCP

Professor of Medicine (Diabetes and Maternal Health)

Leeds Institute of Cardiovascular and Metabolic Medicine

Leeds Centre for Diabetes and Endocrinology

Leeds

UK

Disclosures

ES has received honoraria for talks given by Abbott Diabetes Care and Lilly Diabetes Care. ES has received research grant support from Abbott Diabetes Care in conjunction with the Medical Research Council (MRC) through an MRC industry collaboration agreement - this has gone directly to her University of Leeds employer.

Rebecca Spencer, MBChB, BSc, MRCOG, PhD

NIHR Clinical Lecturer in Obstetrics and Gynaecology

University of Leeds

Leeds

UK

Disclosures

RS is in receipt of a National Institute for Health and Care Research Clinical Lectureship and an Academy of Medical Sciences Starter Grant. RS has acted as an unpaid consultant to Comanche Biopharma, who are developing a novel therapy for pre-eclampsia.

Acknowledgements

Dr Scott and Dr Spencer would like to gratefully acknowledge Dr Ellen W. Seely, Dr Chloe Zera, Dr Jeremy Soule and Dr Leonard E. Egede, previous contributors to this topic.

Disclosures

EWS and CZ declare that they have no competing interests. JS has undertaken research support and speakers' bureau activity for Novartis, Bristol Myers Squibb, Astra Zeneca, and Sanofi-Aventis. LEE is an author of a number of references cited in this topic.

Peer reviewers

Helen Murphy, MBBch, BAO, FRACP, MD

Clinical Professor in Medicine (Diabetes and Antenatal Care)

University of East Anglia

Norwich

UK

Disclosures

HM sits on the Medtronic (insulin pump and CGM manufacturer) European scientific advisory board. HM has received research support (CGM sensors and insulin pumps) at reduced cost from Medtronic, Dexcom, and Johnson & Johnson. MH has contributed to educational events sponsored by NovoNordisk, Medtronic, Dexcom, and Abbott Diabetes Care.

  • Differentials

    • Type 1 diabetes
    • Type 2 diabetes
    More Differentials
  • Guidelines

    • Standards of care in diabetes - 2023
    • Diabetes in pregnancy: management from preconception to the postnatal period
    More Guidelines
  • Patient information

    Diabetes that develops in pregnancy (gestational diabetes)

    Diabetes: what can I do to keep healthy?

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer